31 citations
,
October 2010 in “Journal of the European Academy of Dermatology and Venereology” The authors concluded that some patients clinically diagnosed with telogen effluvium may actually have alopecia areata incognita, suggested by the presence of dystrophic hairs and development of alopecia patches.
25 citations
,
May 2013 in “Experimental Dermatology” This study found that topical EGF-liposomal solution may protect hair follicles from chemotherapy-induced damage by inducing a catagen-like stage in a mouse model.
18 citations
,
August 2008 in “Journal of Investigative Dermatology” 17-β estradiol and prednisolone may speed up hair regrowth after chemotherapy.
2 citations
,
March 2015 in “Hepatitis Monthly” This case report identified dystrophic anagen effluvium as a previously unreported dermatological side effect of PEG-INF-α-2a/RBV combination therapy in a patient with chronic hepatitis C infection.
1 citations
,
January 2014 in “Hair therapy & transplantation” This case study reports the first extensively interpreted instance of dystrophic telogen effluvium potentially linked to pegylated interferon and ribavirin therapy for chronic hepatitis C, characterized through clinical and trichogram analysis.